ArticleMedical oncology (Northwood, London, England)2011
Bcl-2 expression and triple negative profile in breast carcinoma.
Article in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 37 citations in OpenAlex.
- Spatial transcriptomic analysis of tumour with high and low CAIX expression in TNBC tissue samples using GeoMx™ RNA assay.Histology and histopathology · 2024Article
- MicroRNA-615-5p regulates the proliferation and apoptosis of breast cancer cells by targeting HSF1.Experimental and therapeutic medicine · 2021Article
- Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years).Cancer biomarkers : section A of Disease markers · 2021Article
- MMP-1 is overexpressed in triple-negative breast cancer tissues and the knockdown of MMP-1 expression inhibits tumor cell malignant behaviorsOncology letters · 2019Article
- Prognostic Value of BCL2 in Women Patients with Invasive Breast CancerAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer.International journal of molecular sciences · 2017Review
- Bcl-2 antigen expression in luminal A and triple-negative breast cancer.Medical oncology (Northwood, London, England) · 2017Article
- BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer.Journal of breast cancer · 2016Article
- Apoptosis Phenomena in Squamous Cell Carcinomas and Adenocarcinomas of the Uterine Cervix.Pathology oncology research : POR · 2015Article
- Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).Biomedical reports · 2014Article
- Does the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma?American journal of cancer research · 2013Article
- Outcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell death.Journal of the Korean Surgical Society · 2012Article
- Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.Nucleic acids research · 2012Article
- Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American Women diagnosed with breast cancer.BMC research notes · 2012Article
- Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data.Diagnostic pathology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many biomarkers for breast cancer prognosis have been proposed during the last two decades, among which HER2 and oestrogen receptors are of common use in routine clinical practice. However, in recent years, BCL2 has been recognized as an important prognostic parameter in human breast cancer, although its clinical utility is well established. The aim of this study was to examine the protein expression patterns of BCL2, HER2, oestrogen (ER) and progesterone receptors (PR) and to evaluate their correlation with survival and other prognostic parameters such as tumour size, histological grade and metastasis. We used a retrospective study including 84 Tunisian women with breast cancer. Immunohistochemistry was used to measure protein expression levels of several biomarkers. Association with conventional biopathological factors was analysed by SPSS (version13). The expression rates of BCL2, HER2, ER and PR were, respectively, 69, 62, 58.3 and 51.2%. In univariate analyses, BCL2 was highly correlated with both PR (P < 0.001) and ER (P = 0.006) and also with HER2 expression (P = 0.001). The triple negative profile showed a significant association with SBR (P = 0.016) and BCL2 expression (P = 0.02). In multivariate analyses, a significant association was maintained between BCL2 and both PR and ER (P = 0.02 and P = 0.004, respectively). Survival analysis showed that BCL2 expression was positively correlated with patients survival (P = 0.032). A Bayesian network analysis of all the variables confirmed the high value of BCL2 expression as a predictor of survival. As conclusion, BCL2 expression seems to be a very useful factor that should be in combination with HER2 and ER in breast cancer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.